Back to School: How biopharma can reboot drug development. Access exclusive analysis here

ProNAi: The other interference

While some RNAi technologies have achieved proof of principle in the clinic and brought in big deals over the last couple of years, ProNAi Therapeutics Inc. thinks its DNA interference technology could provide dosing advantages by directly shutting off the target gene rather than seeking to stem the flow of mRNA transcripts. The company's lead DNAi agent, PNT2258, will enter Phase I testing for cancer

Read the full 658 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers